A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination

• Published in: Pulmonary pharmacology & therapeutics 2014-12, Vol.29 (2), p.224-232
• Main Authors: Zanasi, Alessandro, Lecchi, Marzia, Del Forno, Manuela, Fabbri, Elisa, Mastroroberto, Marianna, Mazzolini, Massimiliano, Pisani, Lara, Pandolfi, Paolo, Nava, Stefano, Morselli-Labate, Antonio Maria
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Adult; Aged; Albuterol - administration & dosage; Albuterol - therapeutic use; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - therapeutic use; Cough - drug therapy; Cough - etiology; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ipratropium - administration & dosage; Ipratropium - therapeutic use; Ipratropium bromide; Male; Medical Education; Middle Aged; Night cough; Post-viral cough; Pulmonary/Respiratory; Respiratory Tract Infections - complications; Respiratory Tract Infections - virology; Salbutamol; Spirometry; Upper respiratory tract infection; Young Adult
• ISSN: 1094-5539; 1522-9629
• DOI: 10.1016/j.pupt.2014.07.008

Abstract Post-viral cough is a type of cough originating from upper respiratory tract infections that persists after the infection is resolved. Although it was hypothesized that bronchodilators might have a role in the management of post-viral cough, a clear demonstration of their efficacy is missing. Therefore, we tested the efficacy of a combination of a β-agonist and an anticholinergic agent in reducing post-viral cough with a randomized, double blind, placebo controlled clinical trial. Patients were treated for 10 days with either a nebulized combination of salbutamol 1.875 mg/0.5 mL and ipratropium bromide 0.375 mg/0.5 mL, or a placebo, and followed up for another 10 days. Daytime and nighttime cough severity and spirometry testing were assessed before starting treatment, after 10 and 20 days. Ninety-two patients were randomized to receive placebo ( n  = 46) or the active treatment ( n  = 46); nine of them (4 in the placebo group, 5 in the active treatment group) dropped out from the study. Daytime and nighttime cough severity were significantly reduced in both groups during the study period, but the reduction was more prominent in the active treatment group vs . placebo after 10 days of treatment ( P  = 0.003 for day cough; P  = 0.061 for night cough), whereas at the end of follow-up period cough severity was comparable between the two groups. Small but significant increases in spirometric parameters were observed in the active treatment vs . placebo group, although at the end of follow-up these values returned to be comparable to placebo. The frequency of adverse events was not significantly different between the two groups of patients. We concluded that a combination of a β-agonist and an anticholinergic agent can effectively reduce post-viral cough, and can thus represent a valid option for this type of cough.